Results 171 to 180 of about 2,441 (215)
Some of the next articles are maybe not open access.
Treatment of Complicated Schistosomiasis Mansoni with Oxamniquine
The American Journal of Tropical Medicine and Hygiene, 1978Twenty male patients (mean age 23 years) with Schistosoma mansoni infections (mean egg count 429 +/- 311/g feces) were each treated with oxamniquine orally in a single daily dose of 20 mg/kg for 3 consecutive days. Seventeen patients had hepatosplenomegaly, two of these had ascites. Three patients had diffuse colonic polyposis, one of these had ascites.
G. I. Higashi +3 more
openaire +3 more sources
Current Computer - Aided Drug Design, 2019
BACKGROUND Sulfotransferase family comprises key enzymes involved in drug metabolism. Oxamniquine is a pro-drug converted into its active form by schistosomal sulfotransferase.
F. Ezebuo, I. Uzochukwu
semanticscholar +1 more source
BACKGROUND Sulfotransferase family comprises key enzymes involved in drug metabolism. Oxamniquine is a pro-drug converted into its active form by schistosomal sulfotransferase.
F. Ezebuo, I. Uzochukwu
semanticscholar +1 more source
Fluorimetric determination of oxamniquine in biological fluids
Il Farmaco, 1999A highly sensitive and specific fluorimetric method was developed for the determination of oxamniquine in biological fluids (urine and plasma). The proposed method is based on the reduction of oxamniquine using zinc/calcium chloride to obtain its nitroso derivative.
M. S. Rizk +4 more
openaire +3 more sources
Oxamniquine pharmacokinetics in hepatosplenic schistosomiasis in the Sudan
Journal of Antimicrobial Chemotherapy, 1987Oxamniquine pharmacokinetics were determined in five normal Sudanese subjects and nine Sudanese patients with advanced hepatosplenic schistosomiasis, given 1 g as a single oral dose. There were no significant differences in oxamniquine mean area under the plasma concentration time curve (AUC), plasma half life (T1/2), or time to reach peak ...
T. K. Daneshmend, Mamoun A. Homeida
openaire +3 more sources
Chemotherapy of schistosomal colonic polyposis with oxamniquine
Transactions of the Royal Society of Tropical Medicine and Hygiene, 1978Schistosomal polyposis of the colon is a common complication of schistosomiasis. In severe infections it may be associated with considerable morbidity. Surgery is associated with high morbidity and mortality. Niridazole therapy is of limited therapeutic value because of its hepatotoxicity but oxaminiquine has been found to be effective and safe ...
H.Abd Rabbo +3 more
openaire +3 more sources
The toxicology of the schistosomicidal agent oxamniquine
Drug Development Research, 1984AbstractOxamniquine displayed low acute toxicity in mice, hamsters, and rabbits. In rats, however, oxamniquine was much more toxic, the female being 8–10 times more sensitive than the male; single doses elicited an idiosyncratic sex‐linked hepatic necrosis and bile duct proliferation.
R. M. Quinton +7 more
openaire +2 more sources
Synthesis and evaluation of new oxamniquine derivatives
International Journal of Pharmaceutics, 2002Oxamniquine derivatives were synthesized and evaluated as novel schistosomicide agents. Oxamniquine (1,2,3,4-tetrahydro-2-[[(1-methylethyl)amino]methyl]-7-nitro-6-quinolinemethanol) was submitted to the Mannich reaction, using formaldehyde, paraformaldehyde and acetaldehyde as reagents, and gave three unexpected products: two of them were cyclized on ...
Silvio Barberato Filho +6 more
openaire +3 more sources
Preliminary Investigations of Some Derivatives of Oxamniquine
Journal of Chemotherapy, 1995Oxamniquine is a potent schistosomicide used clinically in the treatment of infections due to Schistosoma mansoni. Although relatively well tolerated, some central nervous system (CNS) effects characterised by convulsions have been reported in a small proportion of the population receiving this drug.
B.A. Marples +3 more
openaire +3 more sources
2023
This chapter explores the development of oxamniquine by Pfizer pharmaceuticals, which the chapter uses as an example of how traditional strategies can be used in the development of a drug where the molecular target is unknown. It describes oxamniquine as an important drug in developing countries.
openaire +1 more source
This chapter explores the development of oxamniquine by Pfizer pharmaceuticals, which the chapter uses as an example of how traditional strategies can be used in the development of a drug where the molecular target is unknown. It describes oxamniquine as an important drug in developing countries.
openaire +1 more source
American Journal of Tropical Medicine and Hygiene, 1994
Schistosoma mansoni infections in mice were treated with subcurative multiple doses of either praziquantel (PZQ) or oxamniquine (OX). With an early exception, the drug treatments commenced when the worms were adult, but before the infections had become ...
Padraic G. Fallon, M. Doenhoff
semanticscholar +1 more source
Schistosoma mansoni infections in mice were treated with subcurative multiple doses of either praziquantel (PZQ) or oxamniquine (OX). With an early exception, the drug treatments commenced when the worms were adult, but before the infections had become ...
Padraic G. Fallon, M. Doenhoff
semanticscholar +1 more source